Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
How would he know? The trial remained blinded.
Based on PR comments in May, no reason why P will not better Otezla.
BioHedge, I think Leo does not have any early read about prurisol trial, simply because:
From clinicaltrials.gov: This study is designed as a randomized, double blind, parallel group, placebo-controlled trial to study the efficacy and safety of two oral doses of Prurisol administered twice daily for twelve weeks to subjects with moderate to severe chronic plaque psoriasis.
If the trial completed by Nov. 30 (as they say) and was unblinded after that (as rules say) then Leo has nothing, yet.
I have elsewhere already conceded to one mistake about Prurisol so I am stating this carefully:
Indications are that Prurisol's performance is at least equal to Regeneron's dubilumab and that for an oral medication should be enough for approval. Caveat being the results so far are from really small trial with somewhat murky history. Hence, my gut feeling is that prurisol PASI 75 will exceed 25 %. But by how much? I dunno, and I am not going to even guess.
After lunch buying will be here soon enough.
as we have discussed prev, ad nauseum: I accept that scientifically minded posters somehow prevailed upon Leo to drop the interim release. This was suggested, in a subtle but clear series of posts. I still wonder if results were good he would have ignored them
See post 205601. Yours. A target yes, but still.
We need to break 1.50 next.
$IPIX
#Leo puts $IPIX on the map
Yep 100% agree.
If you believe your CEO failed to deliver!!!! WHY ARE YOU HERE, thousands of stocks out there to invest..
This is where folks with an agenda take ordinary course of business events and turn them into breach of contract material misrepresentations....there is no reasonable inference from Leos conduct re: Prurisol....there are inferences drawn to fit agendas
Reporting interim results is frowned upon due to the bias it can generate among investigators, patients, and anybody else involved as the rest of the trial is conducted to completion. Much cleaner to just wait. Not sure why they didn't just say they were going to do it that way from the start but I think it is a good decision. Could be that an interested outside party strongly suggested it as it makes the final data readout that much more reliable. That would be my guess.
Well, hopefully the Moon is also just another step on the way to Venus, or even Mars.
oh please all those times it was anticipated and announced?
does not count as a promise?
Sure, why not, let's mince words.......
How about an actual opinion about what counts- no interim released
as opposed to a bunch of caps about what does not matter
c'mon- get in the game
Pretty funny. If anyone had stated 3 days ago IPIX would be holding between 1.04 and 1.10 today they would be ecstatic yet several posters today are negative. Go figure.
BioHedge, great to have your comments.
acne HS eczema
IP planning studies for these problems as one reads through the brilacidin program info on the web site- this is exciting, and very good OM data will have a huge ripple effect of interest across the entire franchise
This is why sell the news may not apply to our company so much.
Because this news is just the beginning-
BioHedge The interim was just about 1/3 of the full trial and B was only 3 days away from going 8 for 9. I'm looking at >75% for B.
IPIX NOW 12:04 AT 311,000 VOLUME.
ON SCOTTRADE.
Echo20
IPIX AT $1.09 AND 288,000 VOLUME AT 12:00 PM. ON SCOTTRADE.
Echo20
Leo NEVER PROMISED. IT WAS ANTICIPATED. BIG DIFFERENCE. PROMISE IS A GUARANTEE. ANTICIPATED IS NOT.
SO LET'S CUT THE CRAP.
The company has never stated this publicly. Patrick Cox stated it in a newsletter. We'll see.
In Reply to 'noretreat'
When was the release indicating OM results in "about a week"?
Leo promised, and then failed to deliver
please share with us your thoughts on this issue, if you dismiss my ideas, and I am all ears
I am of that opinion also Pete!
Buyers picking up shares today since tomorrow they will very likely be more expensive.
The moon is $4, the International Space station is $3, and Mt Everest is $2.50.
2.00 is hopefully just a step on the way. :)
the stage is yours:
please, sir, your reading of the vanishing interim data
If he actually saw the interim and the results were so bad not to release them, then why did he even complete the trial? That makes no sense. Keep running the trail and spend lots of money to continue hiding it from the shareholders. Yeah right. Makes a lot of sense.
My take is that a Prurisol deal puts IPIX in a whole new ballgame. Maybe that is why Leo has changed his modus operandi, he doesn't want to screw up a deal by talking too much? At least that is another possibility compared to thinking it is based on not quite stellar results.
This an excellent positive consolidation: up several cents from yesterday’s close, but inside the candle’s long wick. Frankly I’d like to see it take today, tomorrow and Monday to engulf that wick then followed immediately by news (OM, of course). On the 10 minute chart that would complete a cup and handle, but that handle would look like that of a long-handled ladle. A very long-handled ladle, stretching to the moon, or $2, which ever is closer.
here we go....the worst kind of tea leaf reading
agreed of course that leo's general policy of not being shy to release good news makes prurisol silence tough to take..So:
he is quiet because he decided interim data release really was against trial protocol
or, he is quiet because the trial is not a success
woulda been nice for him to explain why he dropped the planned interim release.
Still a bargain at 1.08... Even after the run-up this should trade above 3 with a successful OM trial.
Can't be 12% every day...
sox040713, I agree about statistical significance.
My thinking is that IF stat. significance with 61 subjects will be extraorinarily good, say well below 0.01, FDA may consider granting accelerated approval. It has done so before.
Otherwise, what I have seen done in past, p value below, say, 0.25 or some equivalent measure like difference in incidence rates better than some pre-specified value in P2 trial with 61 subjects is good enough indication to warrant P3.
I use olaratumab , again, as an example, because the approval is barely one year old. If I remember correctly Lilly designed P2 trial so that p in PFS better than 0.2 with 133 subjects would be good enough to proceed to P3. They scored p=0.0615 for PFS and p=0.0003 for OS. The rest is history: FDA granted AA based on the OS in P2 study and Lilly is busy running confirmatory studies, as required by FDA.
True. Think about HOW HARD it is to statistically advance to Phase 3. Something like 75% of all drugs do not go past phase 2. That puts all in perspective and will make trial successes more meaningful.
Agreed on that. Folks have picked up on how when IPIX is jazzed on something, boy do you hear about it! That we’ve been hearing about Brilacidin for IBD and Brilacidin for OM, tells me it’s not bullshit, and they have something stacking up. I am very keen for a Kevetrin update, as positive MOA dileneation and demonstrates clinical benefit in the trial now should spell lucrative early deals, as oncology is the money train of the world. Pharmas thrown big bucks at oncology all day long. And the p53 holy grail is prized. Prurisol, agree again. Since there is only one approved oral for Psoriasis in the world AND it really isn’t that good of a drug, there’s room for more treatments especially safe ones. Why not try taking Prurisol and Otezla at THE same time. People mentioned pruritis—stop the itch, sufferers will line up. It’s a big space and room for different treatments. Prurisol May not beat Otezla on pasi but maybe crushes it in other important categories. Time will tell,
Hoping it does crush it in all. In mean time, OM obsessed and always watching for a partnership which would validate and transform the Rodney danger field of pharmas over night. Good luck to all and pray for us down here in CA.
Losing some steam, we'll see if buyers step in here... 1.10 mark is the key today...
Thank you for the Prurisol realism. I will take a hit by pitch for that particular ipix compound.
Your baseball analogy is good, but even a 350 hitter will smack one out every so often. I get you don’t want to overdo expectations and appreciate your sobering comments regarding results. There little worse than overwrought expectations being dashed.
I still think an argument can be made this stock should be closer to $2.00 pre-results. That could still happen, I suppose.
You see brick wall. I see support level. We've stayed pretty solid the last few months despite your predictions of 60s. News will move it up again when imminent results are released.
batting .350 makes you millions and a place in the Hall of Fame....take that all day, everyday
I hope you're right on the Prurisol front. The only people who have a gut feel, are those looking at the raw data. But my experience has been that Leo has never been known to play his cards close to the vest. The fact that he hasn't been dropping hints about Prurisol tells me a lot about how the trail is going . Not that it's been a bust but it's certainly not a homerun (again just my opinion).
To reiterate, I'm reading the first cuts of the Prurisol data are murky and they really won't know the results until all the data is gathered and analyzed. Again, a 10-15% separation from placebo for Pruisol would be the same as what Otezla had and that's a multi-billion dollar drug.
My whole point is that we don't need to hit home-runs at every at bat... just get on base consistently and the multi-million dollar contracts will come flowing in. Who is more valuable to a team, a guy who bats .350 or a guy who crushes it every now and then? I'll take the .350 batter over a home-run hitter any day of the week.
I don't think there is any way the results of a larger trial will be better than interim data (that bar is crazy high). All we need is a statistically meaningful difference from the placebo arm. That will mean success and a bright future for the company.
The good news is that we're probably less than a week away from getting the data.
The best case for timing is next week on results. I hope you’re right and we get them Tuesday. If results are as good as (better than?) interim then the timing and the holidays won’t really matter.
A Prurisol release that follows that rivals Otezla, and IPIX at $15-20 overnight...
How about an after hours result PR;). With a Monday partner PR? That would confuse the chartists
Plus....iPIX is done with phase 2. While the only other competitor out there with the same preventative primary outcome will start dosing their phase 2 next year.
We are a couple years ahead and they are just starting a phase 2 on a hunch the drug should work in OM from the MOA on a separate indication.
If we see the same results as the interim, it would be an absolute moon shot result. And in my opinion, there is almost no way the numbers hold, to those levels, in a larger data set. I've always learned to temper my expectations in life and even more so in bio-tech investing. But, the great thing with B-OM is that there is no current effective treatment (bad for patients good for IPIX's new offering).
Overcoming the placebo effect is hard (look at the silence around Prurisol - had the numbers been coming in crazy good, we'd have heard rumblings). Take Otezla, there was a lot of board chatter that talked about how narrowly Otezla beat the placebo (like 10-15% or so if I remember correctly) but look at the revenues it's generated. I think the same can happen for B-OM.
We don't need to hit a grand-slam for this to be worth significant $$$. We just need it to work in a statistically meaningful way. As long as we get a decent spread from the placebo arm, we're golden.
My take is the interim was SO good, but a small population. Also, severe chemo patients are a difficult subject group (ie anything can happen that is in gods hands). My take alone is: a trial pass (not fail) with a clear and evident spread between the arms (ie that clearly shows the drug works and has helped a high enough percentage of the population to be meaningful)—and in this case you can draw comps from other om trials. Worth noting how HiGH of a bar ipix set in trial design: prevention and duration—almost unheard of by other pharmas confronting. Ipix has big balls. I’m on the edge of my seat to see how the trial unfolds.
KMBJN, I stand corrected.
Somehow that press release did not get my attention. $6.2 % subjects initially at IGA 3 DID improve to IGAS 0/1, which indicates better performance than regeneron's dupilumab (sort of fitting name if derived from dubious).
I usually go by presentations at scientific conferences because data in presentations tend to be easier to verify (more info). This time my data is from the meeting in Boston Sept 19, 2016. The meeting date postdates the press release. Anyhow, THE PERTINENT POINT is that ALL September 2016 presentation slides ARE consistent with the press release giving 46.2 percent success rate.
The evil here and abroad WILL NOT HOLD THIS DOWN MUCH LONGER....IPIX will be put on a righteous pedestal where it belongs amongst big bio-pharma in the pharmaceutical industry! .....way to much going on and IPIX guns are loaded ready to shoot back at the critics and shorters.
B-OM results due out any day. Certainly not a time to be short.
Followers
|
977
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
402945
|
Created
|
05/10/08
|
Type
|
Free
|
Moderators zandant Minnesinger sunspotter snayeman loanranger frenchbroad |
Innovation Pharmaceuticals Inc. (IPIX)
$IPIX NEWS - http://ipharminc.com/press-release
SEC Filings https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
From the most recent 10-K:
There are doubts about our ability to continue as a going concern.
We have generated revenue of $0 and $18,000 for the fiscal years ended June 30, 2023 and 2022, respectively and have an accumulated deficit of $125.3 million through June 30, 2023. These factors raise substantial doubt about our ability to continue as a going concern.
We need to raise substantial additional capital in the future to fund our operations and we may be unable to raise such funds when needed and on acceptable terms, which could prevent us from fully implementing our business, operating and development plans.
We currently have an approximate $1.0 million cash balance as of the date of this filing, but that is insufficient to complete the development and commercialization of any of our proposed products. We expect to incur costs of approximately $1.8 million in the upcoming fiscal year ending June 30, 2024 to operate our business in accordance with our business plans and budgets.
We have limited experience in drug and formulation development, the conduct of clinical trials, and may not be able to successfully develop any drugs.
Development of pharmaceutical products is a risky and time-consuming process subject to a number of factors, many of which are outside of our control. We are subject to regulatory authority permissions and approvals, most importantly the FDA. Our drug candidate(s)/indications are at early and mid-stages of development. Consequently, we can provide no assurance of the successful and timely development of new drugs, and the failure to do so could cause us to cease operations.
We may elect to deregister our common stock under the Exchange Act and suspend our reporting obligations. Such deregistration and suspension would result in less disclosure about us and may negatively affect the liquidity and trading prices of our common stock.
http://www.ipharminc.com/
About Innovation Pharmaceuticals Inc.:
Established in 2007, and headquartered in Wakefield, Massachusetts, Innovation Pharmaceuticals Inc. (formerly Cellceutix Corporation) is a publicly traded biopharmaceutical company dedicated to discovering and advancing innovative medical therapies with dermatology, oncology, anti-inflammatory and antibiotic applications.
Through ongoing research and drug development efforts, Innovation is focused on improving the clinical care of patients, as well as growing shareholder value. Our team consists of a diverse and accomplished group of professionals working together toward achieving this common goal.
IPIX CEO - "The Company historically devoted most of its efforts and resources on business development, regulatory matters, and clinical trials. Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully." "In general, we expect to concentrate on product development and engage in a limited way in product discovery, avoiding the significant investment of time and financial resources that is generally required for a promising compound to be identified and brought into clinical trials." Source - https://www.sec.gov/ix?doc=/Archives/edgar/data/1355250/000147793223003414/ipix_10q.htm
More information is available at http://www.ipharminc.com.
Management: http://www.ipharminc.com/senior-management/
Scientific Advisors: http://www.ipharminc.com/scientific-advisors/
Clinical Trials: https://clinicaltrials.gov/ct2/results?cond=&term=%22Innovation+Pharmaceuticals%2C+Inc.%22++&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Trials under previous name: https://clinicaltrials.gov/ct2/results?cond=&term=cellceutix&cntry=&state=&city=&dist=&Search=Search&flds=abcefgps
Product Pipeline: http://www.ipharminc.com/therapeutic-areas/
Recent News and Press Releases:
https://finance.yahoo.com/quote/IPIX?p=IPIX
http://www.ipharminc.com/press-release/
SEC Filings (CIK:0001355250): https://www.sec.gov/cgi-bin/browse-edgar?company=Innovation+Pharmaceutical&owner=exclude&action=getcompany
Transfer Agent:
West Coast Stock Transfer, Inc.
721 N. Vulcan Ave. Ste. 205
Encinitas, CA 92024
(619) 664-4780 p
(760) 452-4423 f
cs@wcsti.com
http://www.westcoaststocktransfer.com
Share Structure: See SEC filing link above for current share structure
Investor Relations:
http://www.ipharminc.com/new-faq/
http://www.ipharminc.com/contact-us-1
Chart: https://stockcharts.com/h-sc/ui?s=IPIX
All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.
Also, keep in mind that moderators may or may not have a position in said stock. Being a moderator isn’t a sign of endorsement.
Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |